Jan Siehl

608 total citations
28 papers, 385 citations indexed

About

Jan Siehl is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Jan Siehl has authored 28 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Pathology and Forensic Medicine and 8 papers in Molecular Biology. Recurrent topics in Jan Siehl's work include Lymphoma Diagnosis and Treatment (11 papers), Viral-associated cancers and disorders (8 papers) and Renal and related cancers (4 papers). Jan Siehl is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), Viral-associated cancers and disorders (8 papers) and Renal and related cancers (4 papers). Jan Siehl collaborates with scholars based in Germany, United States and Austria. Jan Siehl's co-authors include Eckhard Thiel, Ulrich Keilholz, Hans D. Menssen, Alexander Schmittel, Marcus Hentrich, Christoph Wyen, R. Schuster, Markus Müller, Nikolaos E. Bechrakis and Michael Foerster and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Jan Siehl

25 papers receiving 382 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Siehl Germany 12 205 130 127 72 59 28 385
Caner Saygin United States 11 174 0.8× 108 0.8× 104 0.8× 150 2.1× 38 0.6× 29 449
Peter Forsyth United Kingdom 7 103 0.5× 152 1.2× 104 0.8× 130 1.8× 50 0.8× 14 391
Naoto Fujita Japan 12 136 0.7× 189 1.5× 51 0.4× 106 1.5× 37 0.6× 42 392
Öner Doğan Türkiye 11 128 0.6× 127 1.0× 78 0.6× 61 0.8× 51 0.9× 56 404
Anna Maria Frustaci Italy 15 111 0.5× 133 1.0× 131 1.0× 181 2.5× 39 0.7× 63 515
Thomas L. Cibull United States 11 139 0.7× 166 1.3× 76 0.6× 37 0.5× 96 1.6× 32 388
Tomoko Yanai Japan 10 174 0.8× 32 0.2× 109 0.9× 52 0.7× 42 0.7× 29 399
Susan R. Wiersma United States 13 78 0.4× 54 0.4× 137 1.1× 260 3.6× 38 0.6× 16 517
Elisa Carraro Italy 12 104 0.5× 125 1.0× 88 0.7× 108 1.5× 60 1.0× 37 392
Anna Demurtas Italy 11 96 0.5× 191 1.5× 64 0.5× 41 0.6× 27 0.5× 23 389

Countries citing papers authored by Jan Siehl

Since Specialization
Citations

This map shows the geographic impact of Jan Siehl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Siehl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Siehl more than expected).

Fields of papers citing papers by Jan Siehl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Siehl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Siehl. The network helps show where Jan Siehl may publish in the future.

Co-authorship network of co-authors of Jan Siehl

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Siehl. A scholar is included among the top collaborators of Jan Siehl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Siehl. Jan Siehl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hentrich, Marcus, Markus Müller, Christoph Wyen, et al.. (2024). Stage‐adapted treatment of HIV‐associated Hodgkin lymphoma: Long‐term results of a prospective, multicenter study. HemaSphere. 8(7). e68–e68. 1 indexed citations
2.
Schommers, Philipp, Daniel Gillor, Marcus Hentrich, et al.. (2018). Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 103(5). 857–864. 22 indexed citations
3.
Siehl, Jan, et al.. (2017). HIV-Associated Lung Cancer. Oncology Research and Treatment. 40(3). 88–92. 11 indexed citations
4.
Hentrich, Marcus, Christoph Wyen, Daniel Gillor, et al.. (2016). Lymphoma-associated mortality in the German HIV-lymphoma cohort study.. Journal of Clinical Oncology. 34(15_suppl). 7550–7550.
5.
6.
Wyen, Christoph, Björn‐Erik Ole Jensen, Marcus Hentrich, et al.. (2011). Treatment of AIDS-related lymphomas. AIDS. 26(4). 457–464. 22 indexed citations
7.
Busse, Antonia, Nicola Gökbuget, Jan Siehl, et al.. (2009). Wilms’ tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. Annals of Hematology. 88(12). 1199–1205. 21 indexed citations
8.
Siehl, Jan & Eckhard Thiel. (2007). C-kit, GIST, and Imatinib. Recent results in cancer research. 176. 145–151. 34 indexed citations
9.
Busse, Antonia, Gero Hütter, Jan Siehl, et al.. (2007). A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma. Leukemia & lymphoma. 48(9). 1755–1763.
10.
11.
Siehl, Jan, E. Thiel, Alexander Schmittel, Gero Hütter, & Ulrich Keilholz. (2006). Liposomal anthracyclines and ifosfamide in the first line treatment of advanced soft tissue sarcomas: A two cohort phase II study. Journal of Clinical Oncology. 24(18_suppl). 9563–9563.
12.
Schmittel, Alexander, Martin Schmidt‐Hieber, Nikolaos E. Bechrakis, et al.. (2006). A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Journal of Clinical Oncology. 24(18_suppl). 8018–8018. 9 indexed citations
13.
Siehl, Jan, Eckhard Thiel, Alexander Schmittel, et al.. (2005). Ifosfamide/liposomal daunorubicin is a well tolerated and active first‐line chemotherapy regimen in advanced soft tissue sarcoma. Cancer. 104(3). 611–617. 21 indexed citations
14.
Schmittel, Alexander, R. Schuster, Nikolaos E. Bechrakis, et al.. (2005). A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma. Melanoma Research. 15(5). 447–451. 30 indexed citations
15.
Keilholz, Ulrich, R. Schuster, Alexander Schmittel, et al.. (2004). A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours. European Journal of Cancer. 40(14). 2047–2052. 14 indexed citations
16.
Siehl, Jan, Eckhard Thiel, Emilian Snarski, et al.. (2003). Possible regulation of Wilms’ tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA‐1 in human acute myeloid leukaemias. British Journal of Haematology. 123(2). 235–242. 25 indexed citations
17.
Menssen, Hans D., Jan Siehl, & Eckhard Thiel. (2002). Wilms Tumor Gene (WT1) Expression as a Panleukemic Marker. International Journal of Hematology. 76(2). 103–109. 25 indexed citations
18.
Szelényi, Hubert, E.D. Kreuser, Ulrich Keilholz, et al.. (2001). Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma. Annals of Oncology. 12(1). 105–108. 3 indexed citations
19.
Seidl, Christian, Jan Siehl, Arnold Ganser, et al.. (2000). Platelet Glycoprotein Expression in Patients with Myelodysplastic Syndrome. Thrombosis Research. 100(1). 27–34. 7 indexed citations
20.
Seidl, Christian, Jan Siehl, C.M. Kirchmaier, & Erhard Seifried. (1997). Analysis of Glycoprotein la, lb, lIb and IV RNA in Platelets: Quantitative Determination Using Fluorescence-Based Polymerase Chain Reaction. Pathophysiology of Haemostasis and Thrombosis. 27(3). 131–139. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caner Saygin Breakdown of academic impact, for papers by Peter Forsyth Breakdown of academic impact, for papers by Naoto Fujita Breakdown of academic impact, for papers by Öner Doğan Breakdown of academic impact, for papers by Anna Maria Frustaci Breakdown of academic impact, for papers by Thomas L. Cibull Breakdown of academic impact, for papers by Tomoko Yanai Breakdown of academic impact, for papers by Susan R. Wiersma Breakdown of academic impact, for papers by Elisa Carraro Breakdown of academic impact, for papers by Anna Demurtas
Rankless by CCL
2026